BC Cancer Agency for Transarterial Chemoembolization (TACE) of Hepatocellular Carcinoma Using Drug-Eluting Bead (DEB) Loaded with DOXOrubicin

**Protocol Code**
UGIDEBTACE

**Tumour Group**
Gastrointestinal

**Contact Physician**
Dr. Howard Lim
Dr. Dave Liu

**ELIGIBILITY:**
- Hepatocellular carcinoma (HCC)
- Reviewed by a multidisciplinary panel:
  - gastroenterologist with HCC experience
  - surgeon with hepato-pancreato-biliary experience
  - interventional radiologist
- ECOG 0 or 1
- A BCCA “Compassionate Access Program” request with appropriate clinical information for each patient must be approved prior to treatment

**EXCLUSIONS:**
- Child-Pugh Class C
- Diffuse HCC (> 50% liver involvement)
- Presence of significant ascites or encephalopathy
- Portal vein thrombosis excluded by Doppler ultrasound or CT
- Bilirubin greater than 50 micrommol/L, AST/ALT greater than 5 times the ULN
- Contraindication for DOXOrubicin

**TESTS:**
- Biphasic CT scan of abdomen within 4-8 weeks prior to the procedure
- Baseline: CBC & diff, platelets, INR, lys, BUN, creatinine, bilirubin, alkaline phosphatase, AST, LDH, albumin, alpha-fetoprotein (AFP)
- Daily for 2 days post-procedure: CBC & diff, platelets, INR, lys, BUN, creatinine, bilirubin, alkaline phosphatase, AST, LDH, albumin, alpha-fetoprotein (AFP)
SUPPORTIVE MEDICATIONS:

Prevention of radiographic contrast dye-mediated nephropathy

If clinically indicated:

<table>
<thead>
<tr>
<th>Drug</th>
<th>Dose</th>
<th>BCCA Administration Guideline</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sodium bicarbonate</td>
<td>150 mEq, 1 hour prior to procedure</td>
<td>IV in 1000 mL D5W at</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- 3 mL/kg/h (max. 330 mL/h) for 1 hour prior to pre-procedure</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- 1 mL/kg*/h (max. 110 mL/h) for 6 hours during and post-procedure</td>
</tr>
</tbody>
</table>

*use a maximum weight of 110 kg to calculate sodium bicarbonate infusion rate

TREATMENT:

<table>
<thead>
<tr>
<th>Drug</th>
<th>Dose</th>
<th>BCCA Administration Guideline</th>
</tr>
</thead>
<tbody>
<tr>
<td>Drug-eluting bead loaded with DOXOribcin</td>
<td>Determined at the time of review based on tumour size</td>
<td>Prepared and ordered by angiography and interventional radiology department</td>
</tr>
</tbody>
</table>

Call Dr. Howard Lim or tumour group delegate @ (604) 877-6000 or 1-800-663-3333 with any problems or questions regarding this treatment program.

Date activated: 1 Feb 2015

Date(s) revised:

References: